Endovascular coils as lung tumour markers in real-time tumour tracking stereotactic radiotherapy: preliminary results

Jean-Briac G Prévost, Joost J Nuyttens, Mischa S Hoogeman, Johan J Pöll, Lukas C van Dijk, Peter M T Pattynama, Jean-Briac G Prévost, Joost J Nuyttens, Mischa S Hoogeman, Johan J Pöll, Lukas C van Dijk, Peter M T Pattynama

Abstract

To evaluate the use of endovascular coils as markers for respiratory motion correction during high-dose stereotactic radiotherapy with the CyberKnife, an image-guided linear accelerator mounted on a robotic arm. Endovascular platinum embolisation coils were used to mark intrapulmonary lesions. The coils were placed in subsegmental pulmonary artery branches in close proximity to the target tumour. This procedure was attempted in 25 patients who were considered unsuitable candidates for standard transthoracic percutaneous insertion. Vascular coils (n = 87) were successfully inserted in 23 of 25 patients. Only minor complications were observed: haemoptysis during the procedure (one patient), development of pleural pain and fever on the day of procedure (one patient), and development of small infiltrative changes distal to the vascular coil (five patients). Fifty-seven coils (66% of total inserted number) could be used as tumour markers for delivery of biologically highly effective radiation doses with automated tracking during CyberKnife radiotherapy. Endovascular markers are safe and allow high-dose radiotherapy of lung tumours with CyberKnife, also in patients who are unsuitable candidates for standard transthoracic percutaneous marker insertion.

Figures

Fig. 1
Fig. 1
A pulmonary arterial catheter used to place a coil. The inserted coil is indicated by the arrow: 179×179 mm (96×96 DPI)
Fig. 2
Fig. 2
Patient with two lung metastases (left and right sided) from a cervical carcinoma. Transthoracic marker insertion in the right cavernous lesion is not feasible. Furthermore, transthoracic placement in both lesions would be related to a major risk for pneumothorax. After endovascular marker placement (coils are indicated by an arrow), both lesions could be treated with CyberKnife. 98×83 mm (96×96 DPI)
Fig. 3
Fig. 3
Non-coiling of the coil because of mismatch between the too large coil windings relative to the small vessel diameter. The coil is therefore unsuitable for automated tracking. The arrows indicate two coils that were unsuitable for tracking due to noncoiling: 137×112 mm (96×96 DPI)
Fig. 4
Fig. 4
a Patient with a second primary NSCLC in the right lung, after having undergone left pneumonectomy 5 years earlier for early stage NSCLC. Surgical treatment was considered not feasible because of the previous pneumonectomy. Conventional radiotherapy, using large margins to take tumour motion into account, would result in increased risk for lung toxicity. Considering the low forced expiratory volume in 1 s of 1,090 ml (38% of predicted), percutaneous insertion of markers with its risk of pneumothorax was considered potentially life-threatening. Endovascular markers were placed (indicated by the arrow) and the patient was treated with CyberKnife by using a total dose of 45 Gy (administered in three treatment sessions). b Follow-up at 10 weeks. Showed complete tumour response. Arrow indicates the coil without remaining tumour): 84×76 mm (96×96 DPI)

References

    1. Graham PH, Gebski VJ, Langlands AO. Radical radiotherapy for early nonsmall cell lung cancer. Int J Radiat Oncol Biol Phys. 1995;31:261–266.
    1. Martel MK, Ten Haken RK, Hazuka MB, et al. Estimation of tumor control probability model parameters from 3-D dose distributions of non-small cell lung cancer patients. Lung Cancer. 1999;24:31–37. doi: 10.1016/S0169-5002(99)00019-7.
    1. Hanley J, Debois MM, Mah D. Deep inspiration breath hold technique for lung tumors: The potential value of target immobilization and reduced lung density in dose escalation. Int J Radiat Oncol Biol Phys. 1999;45:603–611.
    1. Ohara K, Okumura T, Akisada M, et al. Irradiation synchronized with respiration gate. Int J Radiat Oncol Biol Phys. 1989;17:853–857.
    1. Kubo H, Len P, Minohara S. Breathing-synchronized radiotherapy program at the University of California Davis Cancer Center. Med Phys. 2000;27:346–353. doi: 10.1118/1.598837.
    1. Shirato H, Shimizu S, Kunieda T, et al. Physical aspects of a real-time tumor-tracking system for gated radiotherapy. Int J Radiat Oncol Biol Phys. 2000;48:1187–1195. doi: 10.1016/S0360-3016(00)00748-3.
    1. McGarry RC, Papiez L, Williams M, et al. Stereotactic body radiation therapy of early-stage non-small cell lung carcinoma: phase I study. Int J Radiat Oncol Biol Phys. 2005;63(4):1010–1015.
    1. Whyte RI, Crownover R, Murphy MJ, et al. Stereotactic radiosurgery for lung tumors: preliminary report of a phase I trial. Ann Thorac Surg. 2003;75(4):1097–1101. doi: 10.1016/S0003-4975(02)04681-7.
    1. Onishi H, Araki T, Shirato H, et al. Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma. Cancer. 2004;101:1623–1631. doi: 10.1002/cncr.20539.
    1. Timmerman R, Papiez L, McGarry R, et al. Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I non-small cell lung cancer. Chest. 2003;124:1946–1955. doi: 10.1378/chest.124.5.1946.
    1. Van Sonnenberg E, Casola G, Ho M, et al. Difficult thoracic lesions: CT-guided biopsy experience in 150 cases. Radiology. 1988;167:457–461.
    1. Kazerooni EA, Lim FT, Mikhail A, et al. Risk of pneumothorax in CT-guided transthoracic needle aspiration biopsy of the lung. Radiology. 1996;198:371–375.
    1. Cox JE, Chiles C, McManus CM, et al. Transthoracic needle aspiration biopsy: Variables that affect risk of pneumothorax. Radiology. 1999;212:165–168.
    1. Schweikard A, Shiomi H, Adler J. Respiration tracking in radiosurgery. Med Phys. 2004;31:2738–2741. doi: 10.1118/1.1774132.
    1. Charlson ME, Pompei P, Ales K, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis. 1987;40:373–383. doi: 10.1016/0021-9681(87)90171-8.
    1. Omary RA, Bettmann MA, Cardella JF, et al. Quality improvement for the reporting and archiving of interventional radiology procedures. Society of Interventional Radiology Standards of Practice Committee. J Vasc Interv Radiol. 2003;14(suppl):S293–S295.
    1. Shimizu S, Shirato H, Kitamura K, et al. Use of an implanted marker and real-time tracking of the marker for the positioning of prostate and bladder cancers. Int J Radiat Oncol Biol Phys. 2000;48:1591–1597.
    1. Uematsu M, Shioda A, Suda A, et al. Computed tomography-guided frameless stereotactic radiotherapy for stage I non-small cell lung cancer: a 5-year experience. Int J Radiat Oncol Biol Phys. 2001;51:666–670.
    1. Prasad V, Chan RP, Faughnan ME. Embolotherapy of Pulmonary Arteriovenous Malformations: Efficacy of Platinum versus Stainless Steel Coils. J Vasc Interv Radiol. 2004;15:153–160.
    1. Reichner CA, Collins BT, Gagnon GJ, et al. The placement of gold fiducials for CyberKnife Stereotactic Radiosurgery Using a Modified Transbronchial Needle Aspiration Technique. J Bronchol. 2005;12:193–195. doi: 10.1097/01.lab.0000186345.85025.41.
    1. Kupelian PA, Forbes A, Willoughby TR, et al. Implantation and Stability of Metallic Fiducials Within Pulmonary Lesions. Int J Radiat Oncol Biol Phys. 2007;69:777–785.
    1. Shirato H, Harada T, Harabayashi T, et al. Feasibility of insertion/implantation of 2.0-mm-diameter gold internal fiducial markers for precise setup and real-time tumor tracking in radiotherapy. Int J Radiat Oncol Biol Phys. 2003;56:240–247.
    1. Imura M, Yamazaki K, Shirato et al (2005) Insertion and fixation of fiducial markers for setup and tracking of lung tumors in radiotherapy. Int J Radiat Oncol Biol Phys 63:1442–1447
    1. Simon CJ, Dupuy DE, Dipetrillo TA, et al. Pulmonary radiofrequency ablation: longterm safety and efficacy in 153 patients. Radiology. 2007;243:268–275. doi: 10.1148/radiol.2431060088.
    1. Qiao X, Tullgren O, Lax I, et al. The role of radiotherapy in treatment of stage I non-small cell lung cancer. Lung Cancer. 2003;41:1–11. doi: 10.1016/S0169-5002(03)00152-1.
    1. Lee JM, Jin GY, Goldberg SN, et al. Percutaneous radiofrequency ablation for inoperable non-small cell lung cancer and metastases: preliminary report. Radiology. 2004;230:125–134. doi: 10.1148/radiol.2301020934.
    1. Akeboshi M, Yamakado K, Nakatsuka A, et al. Percutaneous radiofrequency ablation of lung neoplasms: initial therapeutic response. J Vasc Interv Radiol. 2004;15:463–470.
    1. de Baere T, Palussiere J, Auperin A, et al. Midterm local efficacy and survival after radiofrequency ablation of lung tumors with minimum follow-up of 1 year: prospective evaluation. Radiology. 2006;240:587–596. doi: 10.1148/radiol.2402050807.
    1. Hiraki T, Sakurai J, Tsuda T, et al. Risk factors for local progression after percutaneous radiofrequency ablation of lung tumors: evaluation based on a preliminary review of 342 tumors. Cancer. 2006;107:2873–2880. doi: 10.1002/cncr.22333.
    1. Yan TD, King J, Sjarif A, et al. Treatment failure after percutaneous radiofrequency ablation for nonsurgical candidates with pulmonary metastases from colorectal carcinoma. Ann Surg Oncol. 2007;14:1718–1726. doi: 10.1245/s10434-006-9271-x.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir